OUR TEAM

Our core pipeline products target the treatment and prevention in disease and infection in women’s health. Our intellectual property includes a strong patent-protected drug pipeline. Our teams in research, board of directors, management and scientific advisors are world class.

Executive Team

Craig R. Travis, M.D. - Chairman of the Board, CEO (Interim) and President

Dr. Travis founded Immugen with the goal to exploit the potential of the endocannabinoid system based on the available scientific literature and available non-proprietary compounds that were known to activate the system. Initially focused on the treatment and transmission of HIV.

Wendy J. Weiser - Chief Operating Officer

Wendy Weiser, with expertise in starting and running small and large organizations of physicians and scientists serves as the Chief Operating Officer

David Fater, CPA - Chief Financial Officer

In addition to serving as Immugen's Chief Financial Officer, David founded and has served as Chief Executive Officer of ALDA & Associates International, a management services firm focused on life
sciences and healthcare since its inception in January 1993.

Latresia Wilson, M.D., Ph.D., MBA, FACEP - Chief Scientific Officer

In addition to serving as Immugen's Chief Scientific Officer, Dr. Wilson is a Fellow of the American College of Emergency Physicians as well as a certified medical marijuana prescriber with an NIH
research background.

Bill W. Massey, Ph.D. - Executive VP, Regulatory Affairs

Dr. Massey is a neuropharmacologist, pharmacogeneticist, life sciences professional, senior executive and entrepreneur. Dr. Massey received his Ph.D. in Pharmacology at the University of Arkansas for Medical Sciences and subsequently was an investigator at the Pritzker School of Medicine’s Drug Abuse Research Center at The University of Chicago.

Tamara Gholson Bavendam, M.D. - Senior VP Strategic Planning

Tamara Bavendam, MD, MS has clinical expertise in female pelvic floor disorders including GSM, was a Senior Medical Director at Pfizer, Inc for 10 years and a Senior Scientific Officer in the National Institutes of Diabetes and Digestive and Kidney Diseases for over 8 years serves as Senior Vice President Strategic Planning.

Robert L. Hirsch, Ph.D. - Senior VP, Director of Immunology

Dr. Robert Hirsch, trained in immunology and virology, has extensive academic and industry research, product development and commercialization experience. He has designed and implemented innovative commercialization and R & D activities in many therapeutic areas, including infectious diseases, immunologicals, oncology, orthopedic, endocrinology, transplantation, neurologic diseases and psychiatric disorders. He has been highly successful in facilitating the development, operations and medical marketing for innovative and important new product developments and product launches.
Dr. Hirsch has managed successful groups at Johnson and Johnson, MedImmune, Inc. (AZ) and Auxillium Pharmaceuticals. He has also acted as Chief Executive Officer and a Board Member at Calibrant Biosystems, Inc. and more recently as Chief Scientific Officer at Green Fence Holdings, a Company focused on cannabis development. For the past several years, Hirsch has managed Hirsch Bio Consulting, LLC. Dr. Hirsch has worked with venture capital groups, technology transfer offices and a number of startup businesses.
Dr. Hirsch received his doctorate from Georgetown University, and continued in academics at The Johns Hopkins University School of Medicine and University of Maryland School of Medicine for 10 years before heading into the pharmaceutical industry.